Luke Evnin Sells 37,104 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Posted by Wayne Rhoads on Dec 14th, 2025

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 37,104 shares of the business’s stock in a transaction dated Wednesday, December 10th. The shares were sold at an average price of $1.06, for a total transaction of $39,330.24. Following the completion of the sale, the director directly owned 2,935,995 shares of the company’s stock, valued at $3,112,154.70. This represents a 1.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Luke Evnin also recently made the following trade(s):

On Friday, December 12th, Luke Evnin sold 17,858 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.08, for a total transaction of $19,286.64.
On Thursday, December 11th, Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.07, for a total transaction of $29,969.63.
On Tuesday, December 9th, Luke Evnin sold 44,570 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.01, for a total value of $45,015.70.
On Monday, December 8th, Luke Evnin sold 34,041 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.99, for a total value of $33,700.59.
On Friday, December 5th, Luke Evnin sold 16,568 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total value of $16,070.96.
On Thursday, December 4th, Luke Evnin sold 53,416 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total value of $51,813.52.
On Wednesday, December 3rd, Luke Evnin sold 36,726 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.87, for a total value of $31,951.62.
On Tuesday, December 2nd, Luke Evnin sold 38,043 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total value of $33,858.27.
On Monday, December 1st, Luke Evnin sold 39,096 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $36,750.24.
On Friday, November 28th, Luke Evnin sold 13,014 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.99, for a total transaction of $12,883.86.

Werewolf Therapeutics Price Performance

Shares of NASDAQ:HOWL opened at $1.10 on Friday. The firm has a 50 day moving average of $1.28 and a 200-day moving average of $1.33. The stock has a market capitalization of $53.39 million, a PE ratio of -0.68 and a beta of 0.74. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a 12 month low of $0.60 and a 12 month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.03. On average, equities research analysts predict that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on HOWL shares. Zacks Research lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 21st. JMP Securities decreased their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 21st. Bank of America lowered their target price on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Finally, Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.75.

Get Our Latest Report on HOWL

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in HOWL. Quadrature Capital Ltd acquired a new position in Werewolf Therapeutics in the 2nd quarter valued at approximately $28,000. Qube Research & Technologies Ltd bought a new stake in shares of Werewolf Therapeutics in the second quarter worth $48,000. Nuveen LLC bought a new stake in shares of Werewolf Therapeutics in the first quarter worth $71,000. AQR Capital Management LLC acquired a new stake in Werewolf Therapeutics in the first quarter valued at $79,000. Finally, Y Intercept Hong Kong Ltd bought a new position in Werewolf Therapeutics during the 2nd quarter worth $92,000. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.